JP2021523720A5 - - Google Patents
Info
- Publication number
- JP2021523720A5 JP2021523720A5 JP2020564156A JP2020564156A JP2021523720A5 JP 2021523720 A5 JP2021523720 A5 JP 2021523720A5 JP 2020564156 A JP2020564156 A JP 2020564156A JP 2020564156 A JP2020564156 A JP 2020564156A JP 2021523720 A5 JP2021523720 A5 JP 2021523720A5
- Authority
- JP
- Japan
- Prior art keywords
- thiouridine
- dsrna molecule
- strand
- molecule according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189998A JP7684373B2 (ja) | 2018-05-16 | 2023-11-07 | オフターゲット効果が低下した修飾ｒｎａ剤 |
| JP2025076285A JP2025113272A (ja) | 2018-05-16 | 2025-05-01 | オフターゲット効果が低下した修飾ｒｎａ剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672405P | 2018-05-16 | 2018-05-16 | |
| US62/672,405 | 2018-05-16 | ||
| US201862719291P | 2018-08-17 | 2018-08-17 | |
| US62/719,291 | 2018-08-17 | ||
| PCT/US2019/032633 WO2019222479A1 (en) | 2018-05-16 | 2019-05-16 | Modified rna agents with reduced off-target effect |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189998A Division JP7684373B2 (ja) | 2018-05-16 | 2023-11-07 | オフターゲット効果が低下した修飾ｒｎａ剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523720A JP2021523720A (ja) | 2021-09-09 |
| JP2021523720A5 true JP2021523720A5 (enExample) | 2022-05-24 |
| JP7384833B2 JP7384833B2 (ja) | 2023-11-21 |
Family
ID=68540971
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564156A Active JP7384833B2 (ja) | 2018-05-16 | 2019-05-16 | オフターゲット効果が低下した修飾ｒｎａ剤 |
| JP2023189998A Active JP7684373B2 (ja) | 2018-05-16 | 2023-11-07 | オフターゲット効果が低下した修飾ｒｎａ剤 |
| JP2025076285A Pending JP2025113272A (ja) | 2018-05-16 | 2025-05-01 | オフターゲット効果が低下した修飾ｒｎａ剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189998A Active JP7684373B2 (ja) | 2018-05-16 | 2023-11-07 | オフターゲット効果が低下した修飾ｒｎａ剤 |
| JP2025076285A Pending JP2025113272A (ja) | 2018-05-16 | 2025-05-01 | オフターゲット効果が低下した修飾ｒｎａ剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US12247203B2 (enExample) |
| EP (1) | EP3802827A4 (enExample) |
| JP (3) | JP7384833B2 (enExample) |
| AU (2) | AU2019270152B2 (enExample) |
| CA (1) | CA3099930A1 (enExample) |
| WO (1) | WO2019222479A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
| EP4114947A1 (en) * | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| KR20230043195A (ko) * | 2020-08-04 | 2023-03-30 | 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 | 오프-타겟 활성이 감소된 변형된 siRNA |
| EP4291654A2 (en) | 2021-02-12 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| CN113073098B (zh) * | 2021-02-20 | 2024-08-20 | 北京理工大学 | 抑制BACE1基因表达的siRNA修饰物及其应用 |
| EP4314296A2 (en) | 2021-03-29 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
| TW202328449A (zh) | 2021-09-24 | 2023-07-16 | 美商艾拉倫製藥公司 | 微管相關蛋白ＴＡＵ（ＭＡＰＴ）ｉＲＮＡ試劑組合物及其使用方法 |
| US11879125B2 (en) | 2022-03-16 | 2024-01-23 | Empirico Inc. | GalNAc compositions for improving siRNA bioavailability |
| AU2023245603A1 (en) | 2022-03-28 | 2024-11-07 | Empirico Inc. | Modified oligonucleotides |
| AU2023313030A1 (en) * | 2022-07-27 | 2025-01-09 | E-Therapeutics Plc | Nucleic acid compounds |
| WO2024073732A1 (en) * | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
| EP4700125A2 (en) * | 2023-04-21 | 2026-02-25 | Suzhou Siran Biotechnology Co., Ltd. | Oligomeric nucleic acid, and preparation method therefore and use thereof |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| US12454693B1 (en) * | 2024-09-27 | 2025-10-28 | Dexcel Pharma Technologies Ltd. | Nucleic acids for inhibiting expression of transferrin receptor 2 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7812149B2 (en) * | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US20050032069A1 (en) * | 2002-11-05 | 2005-02-10 | Muthiah Manoharan | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation |
| EP2152877A2 (en) * | 2007-05-02 | 2010-02-17 | Sirna Therapeutics Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| CN102753187A (zh) | 2009-06-03 | 2012-10-24 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| EP2563922A1 (en) | 2010-04-26 | 2013-03-06 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| US10119136B2 (en) | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| US11504391B1 (en) | 2016-11-23 | 2022-11-22 | Alnylam Pharmaceuticals, Inc. | Modified RNA agents with reduced off-target effect |
-
2019
- 2019-05-16 JP JP2020564156A patent/JP7384833B2/ja active Active
- 2019-05-16 AU AU2019270152A patent/AU2019270152B2/en active Active
- 2019-05-16 CA CA3099930A patent/CA3099930A1/en active Pending
- 2019-05-16 US US17/055,710 patent/US12247203B2/en active Active
- 2019-05-16 WO PCT/US2019/032633 patent/WO2019222479A1/en not_active Ceased
- 2019-05-16 EP EP19803000.9A patent/EP3802827A4/en active Pending
-
2022
- 2022-05-13 US US17/743,663 patent/US12275938B2/en active Active
-
2023
- 2023-11-07 JP JP2023189998A patent/JP7684373B2/ja active Active
-
2024
- 2024-12-04 US US18/968,749 patent/US20250207131A1/en active Pending
-
2025
- 2025-05-01 JP JP2025076285A patent/JP2025113272A/ja active Pending
- 2025-07-22 AU AU2025206406A patent/AU2025206406A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523720A5 (enExample) | ||
| CN109890207B (zh) | 包含可逆修饰的寡核苷酸的组合物及其用途 | |
| KR102493872B1 (ko) | 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드 | |
| IL316808A (en) | Modified double-stranded RNA materials and their uses | |
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| CN113286803A (zh) | S-抗原转运抑制寡核苷酸聚合物和方法 | |
| CN110475784B (zh) | 用于制备立体限定硫代磷酸酯寡核苷酸的正交保护基 | |
| JP7476101B2 (ja) | ホスホロジチオアートヌクレオシド間結合を含むギャップマーオリゴヌクレオチド | |
| CN116655715B (zh) | 一种GalNAc衍生物、缀合物、组合物以及它们的用途 | |
| JP2022550979A5 (enExample) | ||
| WO2025157271A1 (zh) | 一种抑制f11基因表达的核酸分子 | |
| CN121194983A (zh) | 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸 | |
| CN116854753B (zh) | 一种化合物、缀合物、组合物以及它们的用途 | |
| CN110446718A (zh) | Unylinker快速裂解 | |
| CN121816417A (zh) | 双链寡核苷酸药剂和其用途 | |
| JP7476102B2 (ja) | ホスホロジチオアートヌクレオシド間結合を含むオリゴヌクレオチド | |
| EP2854813B1 (en) | Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them | |
| CN121532510A (zh) | Cfb抑制剂组合物及其应用 | |
| CN120917033A (zh) | 化合物、缀合物、组合物以及它们的用途 | |
| JP2025509552A5 (enExample) | ||
| TWI900022B (zh) | GalNAc化合物、綴合物、組合物以及它們的用途 | |
| CN119019475B (zh) | GalNAc化合物、缀合物、组合物以及它们的用途 | |
| JP2023127483A (ja) | ２’位にアミノスルホニルアルコキシ基を有する新規人工核酸 | |
| HK40017810A (en) | Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides | |
| Rejman et al. | Synthesis of 4'-N pyrrolidine nucleosides, nucleotides, and oligonucleotides |